Veracyte Inc [VCYT] stock is trading at $35.81, up 2.96%. An important factor to consider is whether the stock is rising or falling in short-term value. The VCYT shares have gain 2.52% over the last week, with a monthly amount glided 12.50%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Veracyte Inc [NASDAQ: VCYT] stock has seen the most recent analyst activity on March 20, 2025, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $45. Previously, Goldman downgraded its rating to Neutral on December 05, 2024, and dropped its price target to $37. On November 15, 2024, Wolfe Research initiated with a Outperform rating and assigned a price target of $50 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $43 on October 16, 2024. Guggenheim initiated its recommendation with a Buy and recommended $40 as its price target on October 10, 2024. Needham reiterated a Buy rating for this stock on February 23, 2024, and upped its price target to $33. In a note dated January 18, 2023, Raymond James downgraded an Mkt Perform rating on this stock.
Veracyte Inc [VCYT] stock has fluctuated between $22.61 and $47.32 over the past year. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. Veracyte Inc [NASDAQ: VCYT] shares were valued at $35.81 at the most recent close of the market. An investor can expect a potential drop of -21.81% based on the average VCYT price forecast.
Analyzing the VCYT fundamentals
Veracyte Inc [NASDAQ:VCYT] reported sales of 479.13M for the trailing twelve months, which represents a growth of 13.75%. Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at 0.03%, Pretax Profit Margin comes in at 0.06%, and Net Profit Margin reading is 0.05%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.02 and Total Capital is 0.01. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 35.23 points at the first support level, and at 34.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 36.26, and for the 2nd resistance point, it is at 36.72.
Ratios To Look Out For
For context, Veracyte Inc’s Current Ratio is 5.43. On the other hand, the Quick Ratio is 5.10, and the Cash Ratio is 2.87. Considering the valuation of this stock, the price to sales ratio is 5.88, the price to book ratio is 2.31 and price to earnings (TTM) ratio is 107.63.
Transactions by insiders
Recent insider trading involved Febbo Phillip G., Chief Scientific & Med Officer, that happened on Oct 06 ’25 when 8349.0 shares were sold. Officer, PHILLIP FEBBO completed a deal on Oct 06 ’25 to buy 8349.0 shares. Meanwhile, Chief Commercial Officer-CLIA Leite John sold 2539.0 shares on Oct 01 ’25.
